The Mader (ASX: MAD) update for Q1 FY2024 showed strong momentum however at current share price levels, is it a sound investment?

The Adore Beauty (ASX: ABY) trading update for Q1 FY2024 shows promise but is it capable of becoming more than a mediocre business in the long run?

DUG Technology (ASX: DUG) posted strong results in Q1 FY2024, but is this down to the business or external factors?

There are definitely better opportunities in small-caps after the last 18 months, but I’m still leaning cautious due to inflation.

3 ASX retail stocks reveal falling sales in their trading updates for Q1 FY 2024 but investors should keep an eye on one retailer.

Playside Studios (ASX: PLY) reports record quarterly revenue with growth from the higher margin Original IP division driving the growth.

Ansarada (ASX: AND) is a genuine software business, but the challenge is that demand is potentially quite cyclical.

Spacetalk (ASX: SPA) delivered strong revenue growth in Q1 FY 2024 but investors should pay closer attention to its financial health.

RPM Global (ASX: RUL) will institute investor presentations after their results, including allowing shareholders to ask questions.

Cettire (ASX: CTT) reported rapid growth in quarterly sales in Q1 FY 2024 but questions remain over scalability.

Both RPM Global (ASX: RUL) and SRG Global (ASX: SRG) are reporting strong demand from their mining clients.

Austco Healthcare (ASX: AHC) shares are up around 50% in the last 6 months. But is the investment thesis on track?

Forager (ASX: FOR) has just announced longer term plans that would allow investors to exit much closer to net asset value…

Prophesying is never easy.

Each of these companies have interesting prospects and saw their share price spike on FY 2023 results.

Why did the Pro Medicus share price spike to a record of $78.85 this morning and what is the relevant news for Pro Medicus (ASX: PME)?

The EML Payments share price plunged in 2021 after the Central Bank of Ireland investigated it. So why is the EML share price up?

There are some tantalising aspects to the MedAdvisor (ASX: MDR) thesis, but is it a bit too risky?

The FY 2023 Laserbond results saw record earnings per share and a steady dividend, despite a lack of technology division sales.

Audinate today anounced it will raise up to $70m via a placement worth $50m and an SPP worth $20m, but the CEO sold shares 10 days ago.